Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 537

1.

The misdiagnosis of interstitial cystitis/bladder pain syndrome in a VA population.

Skove SL, Howard LE, Senechal J, De Hoedt A, Bresee C, Cunningham TJ, Barbour KE, Kim J, Freedland SJ, Anger JT.

Neurourol Urodyn. 2019 Jul 14. doi: 10.1002/nau.24100. [Epub ahead of print]

PMID:
31302944
2.

Practice patterns and outcomes of equivocal bone scans for patients with castration-resistant prostate cancer: Results from SEARCH.

Hanyok BT, Everist MM, Howard LE, De Hoedt AM, Aronson WJ, Cooperberg MR, Kane CJ, Amling CL, Terris MK, Freedland SJ.

Asian J Urol. 2019 Jul;6(3):242-248. doi: 10.1016/j.ajur.2019.01.004. Epub 2019 Jan 18.

3.

Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing?

Tay KJ, Polascik TJ, Howard LE, Salama JK, Schulman AA, Chen Z, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ.

Clin Genitourin Cancer. 2019 May 24. pii: S1558-7673(18)30729-8. doi: 10.1016/j.clgc.2019.05.007. [Epub ahead of print]

PMID:
31257075
4.

Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients.

Wei Y, Wu J, Gu W, Qin X, Dai B, Lin G, Gan H, Freedland SJ, Zhu Y, Ye D.

Eur Urol. 2019 Jun 24. pii: S0302-2838(19)30453-1. doi: 10.1016/j.eururo.2019.06.004. [Epub ahead of print]

PMID:
31248605
5.

Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy.

Canter DJ, Freedland S, Rajamani S, Latsis M, Variano M, Halat S, Tward J, Cohen T, Stone S, Schlomm T, Bishoff J, Bardot S.

Prostate Cancer Prostatic Dis. 2019 Jun 27. doi: 10.1038/s41391-019-0159-9. [Epub ahead of print]

PMID:
31243337
6.

Obesity, visceral adiposity, and prostate cancer: What is the role of lifestyle interventions?

Shirazipour CH, Freedland SJ.

Cancer. 2019 Jun 10. doi: 10.1002/cncr.32165. [Epub ahead of print] No abstract available.

PMID:
31179532
7.

Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer.

Williams SB, Shan Y, Ray-Zack MD, Hudgins HK, Jazzar U, Tyler DS, Freedland SJ, Swanson TA, Baillargeon JG, Hu JC, Kaul S, Kamat AM, Gore JL, Mehta HB.

JAMA Surg. 2019 Jun 5:e191629. doi: 10.1001/jamasurg.2019.1629. [Epub ahead of print]

PMID:
31166593
8.

Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.

Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, Amling CL, Aronson WJ, Kane CJ, Terris MK, Zumsteg ZS, Butler S, Osborne JR, Morgan TM, Mehra R, Salami SS, Kishan AU, Wang C, Schaeffer EM, Roach M 3rd, Pisansky TM, Shipley WU, Freedland SJ, Sandler HM, Halabi S, Feng FY, Dignam JJ, Nguyen PL, Schipper MJ, Spratt DE.

JAMA Oncol. 2019 May 23. doi: 10.1001/jamaoncol.2019.0826. [Epub ahead of print]

PMID:
31120534
9.

African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome.

Echevarria MI, Awasthi S, Cheng CH, Berglund AE, Rounbehler RJ, Gerke TA, Takhar M, Davicioni E, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Den RB, Cleveland JL, Park JY, Rayford W, Yamoah K.

J Urol. 2019 Aug;202(2):247-255. doi: 10.1097/JU.0000000000000193. Epub 2019 Jul 8.

PMID:
31107158
10.

Influence of African American race on the association between preoperative biopsy grade group and adverse histopathologic features of radical prostatectomy.

Aminsharifi A, Schulman A, Howard LE, Tay KJ, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ, Polascik TJ.

Cancer. 2019 May 1. doi: 10.1002/cncr.32168. [Epub ahead of print]

PMID:
31042315
11.

Validity of the National Death Index to ascertain the date and cause of death in men having undergone prostatectomy for prostate cancer.

Moghanaki D, Howard LE, De Hoedt A, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ.

Prostate Cancer Prostatic Dis. 2019 Apr 29. doi: 10.1038/s41391-019-0146-1. [Epub ahead of print]

PMID:
31036926
12.

Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database.

Nik-Ahd F, Howard LE, Eisenberg AT, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ.

Cancer. 2019 Apr 29. doi: 10.1002/cncr.32141. [Epub ahead of print]

PMID:
31034601
13.

Dietary inflammatory index (DII) and risk of prostate cancer in a case-control study among Black and White US Veteran men.

Vidal AC, Oyekunle T, Howard LE, Shivappa N, De Hoedt A, Figueiredo JC, Taioli E, Fowke JH, Lin PH, Hebert JR, Freedland SJ.

Prostate Cancer Prostatic Dis. 2019 Apr 12. doi: 10.1038/s41391-019-0143-4. [Epub ahead of print]

PMID:
30980026
14.

Baseline Basal Cell Hyperplasia Is not Associated With Baseline Lower Urinary Tract Symptoms, Baseline Clinical Prostatitis or Prostate Cancer in Repeat Biopsies.

Freitas D, Andriole GL, Freedland SJ, Neto BS, Moreira DM.

Urology. 2019 Jul;129:160-164. doi: 10.1016/j.urology.2019.02.034. Epub 2019 Mar 23.

PMID:
30914334
15.

MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.

Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB.

Prostate Cancer Prostatic Dis. 2019 Feb 25. doi: 10.1038/s41391-019-0134-5. [Epub ahead of print]

PMID:
30804427
16.

Blood and dietary magnesium levels are not linked with lower prostate cancer risk in black or white men.

Fowke JH, Koyama T, Dai Q, Zheng SL, Xu J, Howard LE, Freedland SJ.

Cancer Lett. 2019 May 1;449:99-105. doi: 10.1016/j.canlet.2019.02.023. Epub 2019 Feb 15.

PMID:
30776477
17.

The association of atrophy in baseline prostate biopsy and lower prostate cancer grade in radical prostatectomy specimens.

Freitas DMO, Andriole GL, Castro-Santamaria R, Freedland SJ, Moreira DM.

Scand J Urol. 2018 Oct - Dec;52(5-6):328-332. doi: 10.1080/21681805.2018.1551244. Epub 2019 Feb 14.

PMID:
30762450
18.

First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH.

Griffin K, Csizmadi I, Howard LE, Pomann GM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Beebe-Dimmer J, Freedland SJ.

Cancer Causes Control. 2019 Mar;30(3):259-269. doi: 10.1007/s10552-019-1133-5. Epub 2019 Jan 30.

PMID:
30701374
19.

A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial.

Freedland SJ, Howard L, Allen J, Smith J, Stout J, Aronson W, Inman BA, Armstrong AJ, George D, Westman E, Lin PH.

Prostate Cancer Prostatic Dis. 2019 Jan 21. doi: 10.1038/s41391-019-0126-5. [Epub ahead of print]

PMID:
30664736
20.

Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis.

Wallis CJD, Butaney M, Satkunasivam R, Freedland SJ, Patel SP, Hamid O, Pal SK, Klaassen Z.

JAMA Oncol. 2019 Jan 3. doi: 10.1001/jamaoncol.2018.5904. [Epub ahead of print]

PMID:
30605213
21.

Socioeconomic status, race, and long-term outcomes after radical prostatectomy in an equal access health system: Results from the SEARCH database.

Everist MM, Howard LE, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ.

Urol Oncol. 2019 Apr;37(4):289.e11-289.e17. doi: 10.1016/j.urolonc.2018.12.004. Epub 2018 Dec 28.

PMID:
30598238
22.

Rapid Next-Generation Sequencing Method for Prediction of Prostate Cancer Risks.

Fofanov VY, Upadhyay K, Pearlman A, Loke J, O V, Shao Y, Freedland S, Ostrer H.

J Mol Diagn. 2019 Jan;21(1):49-57. doi: 10.1016/j.jmoldx.2018.07.007. Epub 2018 Dec 12.

PMID:
30553750
23.

Interplay between exercise and BMI; results from an equal access, racially diverse biopsy study.

Michael J, Oyekunle T, Howard L, De Hoedt A, Hoyo C, Grant D, Freedland S.

Cancer Causes Control. 2019 Jan;30(1):13-20. doi: 10.1007/s10552-018-1104-2. Epub 2018 Dec 6.

PMID:
30523509
24.

ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis.

Rotinen M, You S, Yang J, Coetzee SG, Reis-Sobreiro M, Huang WC, Huang F, Pan X, Yáñez A, Hazelett DJ, Chu CY, Steadman K, Morrissey CM, Nelson PS, Corey E, Chung LWK, Freedland SJ, Di Vizio D, Garraway IP, Murali R, Knudsen BS, Freeman MR.

Nat Med. 2018 Dec;24(12):1887-1898. doi: 10.1038/s41591-018-0241-1. Epub 2018 Nov 26.

25.

Response to Editorial Comment to Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.

Patel DN, Chapin BF, Freedland SJ.

Int J Urol. 2018 Dec;25(12):1005. doi: 10.1111/iju.13861. Epub 2018 Nov 20. No abstract available.

PMID:
30458585
26.

Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?

Vidal AC, Howard LE, De Hoedt A, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Lechpammer S, Flanders SC, Freedland SJ.

Cancer. 2019 Feb 1;125(3):434-441. doi: 10.1002/cncr.31808. Epub 2018 Nov 14.

PMID:
30427535
27.

Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer.

Berglund AE, Rounbehler RJ, Gerke T, Awasthi S, Cheng CH, Takhar M, Davicioni E, Alshalalfa M, Erho N, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Trock BJ, Den RB, Cleveland JL, Park JY, Dhillon J, Yamoah K.

Prostate Cancer Prostatic Dis. 2019 May;22(2):292-302. doi: 10.1038/s41391-018-0103-4. Epub 2018 Oct 26.

PMID:
30367117
28.

Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database.

Aminsharifi A, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Polascik TJ, Freedland SJ.

Clin Genitourin Cancer. 2019 Feb;17(1):e140-e149. doi: 10.1016/j.clgc.2018.09.020. Epub 2018 Oct 4.

PMID:
30366879
29.

Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database.

Freedland SJ, Branche BL, Howard LE, Hamilton RJ, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Kane CJ; SEARCH Database Study Group.

BJU Int. 2019 Jul;124(1):69-75. doi: 10.1111/bju.14594. Epub 2018 Nov 16.

PMID:
30347135
30.

The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.

Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY.

J Natl Cancer Inst. 2019 Mar 1;111(3):301-310. doi: 10.1093/jnci/djy141.

PMID:
30321406
31.

Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer.

Whitney CA, Howard LE, Freedland SJ, DeHoedt AM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Daskivich TJ.

Prostate Cancer Prostatic Dis. 2019 May;22(2):252-260. doi: 10.1038/s41391-018-0095-0. Epub 2018 Oct 2.

PMID:
30279582
32.

Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.

Patel DN, Jha S, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Chapin BF, Freedland SJ.

Int J Urol. 2018 Dec;25(12):998-1004. doi: 10.1111/iju.13806. Epub 2018 Sep 25.

PMID:
30253446
33.

Enzalutamide treatment for the whole spectrum of CRPC.

Zhao H, Freedland S.

Nat Rev Urol. 2018 Nov;15(11):663-665. doi: 10.1038/s41585-018-0090-1. No abstract available.

PMID:
30242270
34.

Nocturia and associated mortality: observational data from the REDUCE trial.

Bliwise DL, Howard LE, Moreira DM, Andriole GL, Hopp ML, Freedland SJ.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):77-83. doi: 10.1038/s41391-018-0090-5. Epub 2018 Sep 13.

PMID:
30214036
35.

Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an AUA/ASTRO/SUO Guideline Summary.

Bekelman JE, Rumble RB, Freedland SJ.

J Oncol Pract. 2018 Oct;14(10):618-624. doi: 10.1200/JOP.18.00434. Epub 2018 Sep 10. No abstract available.

PMID:
30199312
36.

Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline.

Bekelman JE, Rumble RB, Chen RC, Pisansky TM, Finelli A, Feifer A, Nguyen PL, Loblaw DA, Tagawa ST, Gillessen S, Morgan TM, Liu G, Vapiwala N, Haluschak JJ, Stephenson A, Touijer K, Kungel T, Freedland SJ.

J Clin Oncol. 2018 Sep 5:JCO1800606. doi: 10.1200/JCO.18.00606. [Epub ahead of print]

PMID:
30183466
37.

Statin Therapy to Improve Prostate Cancer Outcomes: Who, When, and for How Long?

Allott EH, Freeman MR, Freedland SJ.

Eur Urol. 2018 Dec;74(6):702-703. doi: 10.1016/j.eururo.2018.08.012. Epub 2018 Aug 31. No abstract available.

PMID:
30177293
38.

Early-Life Alcohol Intake and High-Grade Prostate Cancer: Results from an Equal-Access, Racially Diverse Biopsy Cohort.

Michael J, Howard LE, Markt SC, De Hoedt A, Bailey C, Mucci LA, Freedland SJ, Allott EH.

Cancer Prev Res (Phila). 2018 Oct;11(10):621-628. doi: 10.1158/1940-6207.CAPR-18-0057. Epub 2018 Aug 23.

PMID:
30139875
39.

A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III).

Crawford ED, Koo PJ, Shore N, Slovin SF, Concepcion RS, Freedland SJ, Gomella LG, Karsh L, Keane TE, Maroni P, Penson D, Petrylak DP, Ross A, Mouraviev V, Reiter RE, Divgi C, Yu EY; RADAR III Group.

J Urol. 2019 Apr;201(4):682-692. doi: 10.1016/j.juro.2018.05.164. Review.

PMID:
30077557
40.

The Association of Previous Prostate Biopsy Related Complications and the Type of Complication with Patient Compliance with Rebiopsy Scheme.

Schwarzman LS, Abern MR, Garvey DF, Andriole GL, Freedland SJ, Moreira DM.

J Urol. 2018 Nov;200(5):1062-1067. doi: 10.1016/j.juro.2018.06.018. Epub 2018 Jun 12.

PMID:
29906435
41.

Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study.

Fantony JJ, Howard LE, Csizmadi I, Armstrong AJ, Lark AL, Galet C, Aronson WJ, Freedland SJ.

Biomark Med. 2018 Jul;12(7):727-736. doi: 10.2217/bmm-2017-0322. Epub 2018 Jun 15.

42.

Both acute and chronic inflammation are associated with less perineural invasion in men with prostate cancer on repeat biopsy.

Kuang AG, Nickel JC, Andriole GL, Castro-Santamaria R, Freedland SJ, Moreira DM.

BJU Int. 2019 Jan;123(1):91-97. doi: 10.1111/bju.14428. Epub 2018 Jul 26.

PMID:
29873889
43.

Smoking and Death From Prostate Cancer.

Freedland SJ.

JAMA Oncol. 2018 Jul 1;4(7):961-962. doi: 10.1001/jamaoncol.2018.1070. No abstract available.

PMID:
29800137
44.

Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer.

Allott EH, Masko EM, Freedland AR, Macias E, Pelton K, Solomon KR, Mostaghel EA, Thomas GV, Pizzo SV, Freeman MR, Freedland SJ.

Prostate Cancer Prostatic Dis. 2018 Jun;21(2):196-203. doi: 10.1038/s41391-018-0045-x. Epub 2018 May 23.

45.

PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study.

Patel DN, Feng T, Simon RM, Howard LE, Vidal AC, Moreira DM, Castro-Santamaria R, Roehrborn C, Andriole GL, Freedland SJ.

Prostate Cancer Prostatic Dis. 2018 Jun;21(2):238-244. doi: 10.1038/s41391-018-0044-y. Epub 2018 May 23.

PMID:
29795141
46.

A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts.

Ankerst DP, Straubinger J, Selig K, Guerrios L, De Hoedt A, Hernandez J, Liss MA, Leach RJ, Freedland SJ, Kattan MW, Nam R, Haese A, Montorsi F, Boorjian SA, Cooperberg MR, Poyet C, Vertosick E, Vickers AJ.

Eur Urol. 2018 Aug;74(2):197-203. doi: 10.1016/j.eururo.2018.05.003. Epub 2018 May 16.

PMID:
29778349
47.

Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index.

Aminsharifi A, Howard L, Wu Y, De Hoedt A, Bailey C, Freedland SJ, Polascik TJ.

J Urol. 2018 Oct;200(4):758-766. doi: 10.1016/j.juro.2018.05.016. Epub 2018 Jul 6.

PMID:
29758219
48.

Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer.

Yang L, Roberts D, Takhar M, Erho N, Bibby BAS, Thiruthaneeswaran N, Bhandari V, Cheng WC, Haider S, McCorry AMB, McArt D, Jain S, Alshalalfa M, Ross A, Schaffer E, Den RB, Jeffrey Karnes R, Klein E, Hoskin PJ, Freedland SJ, Lamb AD, Neal DE, Buffa FM, Bristow RG, Boutros PC, Davicioni E, Choudhury A, West CML.

EBioMedicine. 2018 May;31:182-189. doi: 10.1016/j.ebiom.2018.04.019. Epub 2018 Apr 23.

49.

Robust genomic copy number predictor of pan cancer metastasis.

Pearlman A, Upadhyay K, Cole K, Loke J, Sun K, Fineberg S, Freedland SJ, Shao Y, Ostrer H.

Genes Cancer. 2018 Jan;9(1-2):66-77. doi: 10.18632/genesandcancer.165.

50.

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES.

Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16. Review.

PMID:
29673712

Supplemental Content

Loading ...
Support Center